Published in final edited form as:

Bioorg Med Chem Lett. 2008 May 15; 18(10): 3029–3033. doi:10.1016/j.bmcl.2008.04.038.

Synthesis and *in vitro* antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors

Christopher W. am Ende^a, Susan E. Knudson^b, Nina Liu^a, James Childs^c, Todd J. Sullivan^a, Melissa Boyne^d, Hua Xu^a, Yelizaveta Gegina^a, Dennis L. Knudson^b, Francis Johnson^a, Charles A. Peloquin^c, Richard A. Slayden^{d,*}, and Peter J. Tonge^{a,*}

^aInstitute of Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University, Stony Brook, NY 11794-3400.

^bDepartment of Bioagricultural Sciences and Pest Management, Colorado State University, Fort Collins, CO 80523.

^cInfectious Disease Pharmacokinetics Laboratory, National Jewish Medical and Research Center, Denver, CO 80206.

^dDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523-1682.

Abstract

In earlier work structure-based design studies resulted in the discovery of alkyl substituted diphenyl ether inhibitors of InhA, the enoyl reductase from *Mycobacterium tuberculosis*. Compounds such as 5-hexyl-2-phenoxyphenol **19** are nM inhibitors of InhA and inhibit the growth of both sensitive and isoniazid-resistant strains of *Mycobacterium tuberculosis* with MIC₉₀ values of 1–2 µg/mL.

However, despite their promising *in vitro* activity, these compounds have ClogP values of over 5. In efforts to reduce the lipophilicity of the compounds, and enhance potentially enhance compound bioavailability, a series of B ring analogues of **19** were synthesized that contained either heterocyclic nitrogen rings or phenyl rings having amino, nitro, amide or piperazine functions. Compounds **3c**, **3e** and **14a** show comparable MIC₉₀ values to that of **19**, but have improved ClogP values.

Keywords

Tuberculosis; Diaryl ether; enoyl reductase; mycolic acids; InhA; isoniazid

Tuberculosis (TB) is responsible for more than 1.6 million deaths per annum with 8.8 million new cases being reported each year. These numbers make TB one of the leading infectious causes of death, eclipsed only by AIDS. In addition, according to the World Health Organization, the number of multi-drug-resistant and extensively drug-resistant TB cases is growing with almost a half million new cases being reported each year. Therefore, there is an urgent need to develop novel TB chemotherapeutic agents.¹

*Corresponding authors, PJT: Tel.: (631) 632 7907; Email: peter.tonge@sunysb.edu, RAS: Tel.: (970) 491 1925; Email: richard.slayden@colostate.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The current front-line treatment strategy utilizes isoniazid (INH), a pro-drug which inhibits the synthesis of mycolic acids that are essential components required for the integrity of the bacterial cell wall.² INH inhibits InhA, the FabI enoyl reductase (ENR) in the fatty acid synthesis (FAS-II) pathway. However, before INH can inhibit InhA, it must be activated by KatG, a catalase-peroxidase enzyme. The activated form of INH then reacts with NAD⁺ to form the INH-NAD adduct (Scheme 1).^{3–7} A significant number of the strains resistant to INH arise from mutations in KatG.^{8–11} Therefore, the development of an InhA inhibitor which can by-pass this initial activation step should have activity against INH-resistant strains of *Mycobacterium tuberculosis* (MTB).

The diphenyl ether triclosan (Scheme 1) is a potent inhibitor of ENR's from many organisms including *Escherichia coli* and *Plasmodium falciparum*.^{12–20} However this compound only inhibits InhA with a K_i value of 0.2 μM.²¹ Using structure-based drug design we developed a series of alkyl diphenyl ethers that are potent inhibitors of InhA, with K_i values as low as 1 nM and MIC₉₀ values of 1–2 μg/mL against *M. tuberculosis* H37_{Rv}.²² Importantly the alkyl diphenyl ethers display similar MIC values against INH-resistant strains of MTB.²² However, despite their promising *in vitro* activity, these compounds have relatively low solubility and have ClogP values greater than 5, which is likely one reason why they have limited *in vivo* efficacy.²³ Based on the observed relationship between lipophilicity and *in vivo* efficacy, especially as it pertains to antibacterial compounds,^{24, 25} we synthesized a series of analogues that incorporated functionalities designed to increase the polarity of the parent diphenyl ether InhA inhibitors. The effect on compound polarity was estimated by calculating the logP value (ClogP) for each compound synthesized.

In this study we describe two classes of molecules in which alterations have been made to the diphenyl ether 'B' ring. In one series of compounds we have replaced the B ring with isosteric heterocycles that incorporate nitrogen atoms within the ring, thereby causing little steric perturbation to the overall structure of the molecule (Scheme 2). The second series of compounds have nitro, amino, amide and piperazino functionalities incorporated at the *ortho*, *meta*, or *para* positions of the B ring (Scheme 3 and Scheme 4). This second series of compounds was synthesized not only to improve solubility but also to systematically identify positions on the B ring which could be substituted without diminishing biological activity.

The synthesis of the heterocyclic diaryl ether compounds was initiated either by nucleophilic aromatic substitution or by Buchwald-Hartwig cross-coupling of the appropriate nitrogen heterocycle with 4-bromo or chloro-2-methoxy phenol producing **1a–f** (Scheme 2).^{26, 27} This was followed by palladium catalyzed Negishi coupling of the diaryl ethers with hexyl zinc chloride to give **2a–f**.²⁸ Boron tribromide cleavage of the methyl ether was used subsequently to generate the respective phenols, **3a–f**.²⁹ Structural characterization of all compounds was performed using ¹H NMR and ESI/MS.

The synthesis of the nitro, amino and amide-substituted compounds was performed using the series of reactions shown in Scheme 3. Nucleophilic aromatic substitution reactions with fluoronitrobenzenes were first used to generate compounds **4a–c**.²⁷ This was followed by Negishi coupling giving **5a–c** followed by boron tribromide cleavage to give compounds **13a–c** or zinc-mediated reduction giving anilines **6a–c**.^{28–30} Cleavage of the methyl ether gave **14a–c** while acylation of the anilines with acyl chlorides afforded compounds **7, 8** and **9a–c**.^{29, 31} Boron tribromide cleavage then gave the final compounds **10, 11** and **12a–c**.²⁹

The piperazine derivatives were synthesized in a similar fashion starting with nucleophilic aromatic substitution with the 2- or 4-fluorobenzaldehyde to give **13a** and **b** (Scheme 4).²⁷ Subsequently, reductive amination with methyl piperazine and sodium triacetoxyborohydride

produced **14a** and **b**,³² whereas Negishi coupling followed by boron tribromide cleavage gave the final compounds **16a** and **b**.^{28, 29}

The *in vitro* activities of the ultimate products were evaluated using enzyme inhibition and whole cell antibacterial assays as described previously (Table 1–Table 3).^{22, 33, 34} In general, addition of a bulky substituent at either the *ortho*, *meta* or *para* position of the B ring of **19** or incorporation of most aromatic nitrogen heterocycles resulted in a significant reduction in both enzyme inhibition and antibacterial activity (Table 1 and Table 3). In contrast, introduction of either amino or nitro substituents at the *ortho* and *para* positions had only a minimal effect on activity (Table 2). The two most active compounds, **3c** and **14a**, have MIC₉₀ values of 3.13 µg/mL, similar to that of **19**, and have ClogP values of 4.97 and 5.24, respectively, compared to 6.47 for the parent compound (Table 1 and Table 2). In addition it is also worth noting that the pyrazine derivative **3e**, has a ClogP value that is more than an order of magnitude lower than **19**, but still only shows a 3-fold increase in MIC₉₀ compared to the parent (Table 1). In general the MIC values correlated with the IC₅₀ values for enzyme inhibition. Thus *ortho* and *para* amino substituents (**14a,c**) were well tolerated in addition to the *meta* nitro substituent (**13b**). In these three cases the IC₅₀ values obtained using 100 nM InhA approached 50% of the enzyme concentration, indicating that these compounds are tight-binding enzyme inhibitors. Additional IC₅₀ values were determined using 10 and 50 nM InhA in the enzyme assays. Subsequent linear regression analyses of the IC₅₀ values as a function of enzyme concentration yielded estimates for K_i^{app} of 21 ± 3 nM (**13b**), 16 ± 12 nM (**14a**) and 40 ± 3 nM (**14c**). Thus, introduction of a *meta* nitro (**13b**) or an *ortho* amino (**14a**) group into the B ring of the parent compound **19** has only a minor effect on the affinity of the inhibitor for the enzyme. Compound **14a** is of particular interest because this derivative has a MIC₉₀ value that is close to the value determined for **19**. These data provide important information on the structural flexibility of the inhibitor binding-site that will be useful in directing the design of additional compounds.

In conclusion, a series of hexyl diaryl ethers were synthesized in which the B ring of compound **19** has been substituted with a variety of groups, or replaced with nitrogen-containing aromatic heterocycles. Several of these new compounds possess MIC₉₀ and K_i^{app} values similar to that of **19** while having significantly improved ClogP values. Studies are currently underway to determine whether the modifications that we have introduced have resulted in an increase in compound bioavailability and an improvement in their *in vivo* antibacterial activity.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgement

This work was supported by NIH grants AI44639 and AI70383.

References

1. WHO. WHO Report. 2007. www.who.int/tb/publications/global_report/2007/pdf/full.pdf
2. Brennan PJ, Rooney SA, Winder FG. Ir. J. Med. Sci 1970;3:371. [PubMed: 4990357]
3. Johnsson K, King DS, Schultz PG. J. Am. Chem. Soc 1995;117:5009.
4. Marcinkeviciene JA, Magliozzo RS, Blanchard JS. J. Biol. Chem 1995;270:22290. [PubMed: 7673210]
5. Basso LA, Zheng RJ, Blanchard JS. J. Am. Chem. Soc 1996;118:11301.
6. Quemard A, Dessen A, Sugantino M, Jacobs WR Jr, Sacchettini JC, Blanchard JS. J. Am. Chem. Soc 1996;118:1561.
7. Rawat R, Whitty A, Tonge PJ. Proc. Nat. Acad. Sci. U.S.A 2003;100:13881.

8. Zhang Y, Heym B, Allen B, Young D, Cole S. *Nature* 1992;358:591. [PubMed: 1501713]
9. Stoeckle MY, Guan L, Riegler N, Weitzman I, Kreiswirth B, Kornblum J, Laraque F, Riley LW. *J. Infect. Dis* 1993;168:1063. [PubMed: 8376822]
10. Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embden JD. *J. Infect. Dis* 1996;173:196. [PubMed: 8537659]
11. Ramaswamy SV, Reich R, Dou SJ, Jasperse L, Pan X, Wanger A, Quitugua T, Graviss EA. *Antimicrob. Agents Chemother* 2003;47:1241. [PubMed: 12654653]
12. Baldock C, Rafferty JB, Sedelnikova SE, Baker PJ, Stuitje AR, Slabas AR, Hawkes TR, Rice DW. *Science* 1996;274:2107. [PubMed: 8953047]
13. Heath RJ, Yu YT, Shapiro MA, Olson E, Rock CO. *J. Biol. Chem* 1998;273:30316. [PubMed: 9804793]
14. Stewart MJ, Parikh S, Xiao G, Tonge PJ, Kisker C. *J. Mol. Biol* 1999;290:859. [PubMed: 10398587]
15. Heath RJ, White SW, Rock CO. *Prog. Lipid Res* 2001;40:467. [PubMed: 11591436]
16. Surolia N, Surolia A. *Nat. Med* 2001;7:167. [PubMed: 11175846]
17. Perozzo R, Kuo M, Sidhu AS, Valiyaveetil JT, Bittman R, Jacobs WR Jr, Fidock DA, Sacchettini JC. *J. Biol. Chem* 2002;277:13106. [PubMed: 11792710]
18. Kuo MR, Morbidoni HR, Alland D, Sneddon SF, Gourlie BB, Staveski MM, Leonard M, Gregory JS, Janjigian AD, Yee C, Kreiswirth B, Iwamoto H, Perozzo R, Jacobs WR Jr, Sacchettini JC, Fidock DA. *J. Biol. Chem* 2003;278:20851. [PubMed: 12606558]
19. Sivaraman S, Sullivan TJ, Johnson F, Novichenok P, Cui G, Simmerling C, Tonge PJ. *J. Med. Chem* 2004;47:509. [PubMed: 14736233]
20. Freundlich JS, Anderson JW, Sarantakis D, Shieh HM, Yu M, Valderramos JC, Lucumi E, Kuo M, Jacobs WR Jr, Fidock DA, Schiehsler GA, Jacobus DP, Sacchettini JC. *Bioorg. Med. Chem. Lett* 2005;15:5247. [PubMed: 16198563]
21. Parikh SL, Xiao G, Tonge PJ. *Biochemistry* 2000;39:7645. [PubMed: 10869170]
22. Sullivan TJ, Truglio JJ, Boyne ME, Novichenok P, Zhang X, Stratton CF, Li H-J, Kaur T, Amin A, Johnson F, Slayden RA, Kisker C, Tonge PJ. *ACS Chem. Biol.* 2006;1:43. [PubMed: 17163639]
23. Boyne ME, Sullivan TJ, amEnde CW, Lu H, Gruppo V, Heaslip D, Amin AG, Chatterjee D, Lenaerts A, Tonge PJ, Slayden RA. *Antimicrob. Agents Chemother* 2007;51:3562. [PubMed: 17664324]
24. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. *Adv. Drug Deliv. Rev* 2001;46:3. [PubMed: 11259830]
25. O'Shea R, Moser HE. *J. Med. Chem.* 2008
26. Marcoux JF, Doye S, Buchwald SL. *J. Am. Chem. Soc* 1997;119:10539.
27. Marsh G, Stenutz R, Bergman A. *Eur. J. Org. Chem* 2003:2566.
28. Dai CY, Fu GC. *J. Am. Chem. Soc* 2001;123:2719. [PubMed: 11456957]
29. Neumeyer JL, Baidur N, Yuan J, Booth G, Seeman P, Niznik HB. *J. Med. Chem* 1990;33:521. [PubMed: 2405157]
30. Masesane IB, Batsanov AS, Howard JA, Mondal R, Steel PG, Beilstein J. *Org. Chem* 2006;2
31. Deruiter J, Swearingen BE, Wandrekar V, Mayfield CA. *J. Med. Chem* 1989;32:1033. [PubMed: 2496229]
32. Abdel-Magid AF, Carson KG, Harris BD, Maryanoff CA, Shah RD. *J. Org. Chem* 1996;61:3849. [PubMed: 11667239]
33. Collins LA, Franzblau SG. *Antimicrob. Agents Chemother* 1997;41:1004. [PubMed: 9145860]
34. Huang Q, Kirikae F, Kirikae T, Pepe A, Amin A, Respicio L, Slayden RA, Tonge PJ, Ojima I. *J. Med. Chem* 2006;49:463. [PubMed: 16420032]

Scheme 1.
Enoyl reductase inhibitors.

Scheme 2.

Reagents and conditions: (a) K_2CO_3 , DMAc, Δ , Y; (b) $(CuOTf)_2 \cdot PhH$, Cs_2CO_3 , EtOAc, toluene, $120^\circ C$, Y; (c) Hexyl $ZnCl_2$, $Pd(P(t-Bu)_3)_2$, THF/NMP, $130^\circ C$; (d) BBr_3 , DCM, $0^\circ C$ to rt.

Scheme 3.

Reagents and Conditions: (a) K_2CO_3 , DMAc, Δ ; (b) Hexyl $ZnCl_2$, $Pd(P(t-Bu)_3)_2$, THF/NMP, $130^\circ C$; (c) Zn, HCl, EtOH, rt; (d) acyl chloride, NEt_3 , DCM; (e) BBr_3 , DCM, $0^\circ C$ to rt.

Scheme 4.

Reagents and Conditions: (a) K₂CO₃, DMAc, Δ; (b) N-methyl piperazine, NaBH(OAc)₃, DCE; (c) Hexyl ZnCl₂, Pd(P(t-Bu)₃)₂, THF/NMP, 130°C; (d) BBr₃, DCM, 0°C to rt.

Table 1

Inhibition and solubility data for B-ring heterocycles.

Compound	Structure	IC ₅₀ (nM) ^a	MIC ₉₀ (μg·mL ⁻¹)	ClogP ^b	logP
19		11 ± 1 ^c	2.1 ± 0.9	6.47	5.76
3a		11500 ± 1160	50	4.97	5.06
3b		236 ± 31	3.13	4.97	
3c		160 ± 16	3.13	4.97	4.93
3d		8200 ± 980	100.0 ± 0	4.01	4.46
3e		650 ± 60	6.25 ± 0	4.01	4.764
3f		NI ^d	100	5.50	
2d		> 100,000	75 ± 0	4.50	

^aEnzyme concentration is 100 nM.

^bClogP values determined using ChemDraw 8.0.

^cEnzyme concentration is 1 nM.

^dNo inhibition.

Table 2

Inhibition and solubility data for nitro and aniline compounds.

Compound	Structure	IC ₅₀ (nM) ^a	MIC ₉₀ (μg·ml ⁻¹)	ClogP ^b	logP
13a		180 ± 20	12.50	6.21	5.50
13b		48 ± 6 ^c	12.50	6.21	
13c		90 ± 10	25.0 ± 0	6.21	5.64
14a		62 ± 5	3.13	5.24	5.27
14b		1090 ± 90	100 ± 0	5.24	
14c		55 ± 6 ^c	12.50	5.24	4.93

^a Enzyme concentration is 100 nM.

^b ClogP values determined using ChemDraw 8.0.

^c Actual IC₅₀ may be lower than this value.

Table 3
Inhibition and solubility data for amide and piperazine compounds.

Compound	Structure	IC ₅₀ (nM) ^a	MIC ₉₀ (μg·mL ⁻¹)	ClogP ^b	logP
10a		1550 ± 460	>200 ± 0	4.90	5.28
10b		5600 ± 770	100	4.90	
10c		1300 ± 200	50.0 ± 0	4.90	
11a		2360 ± 200	100.00	4.24	
11b		580 ± 40	130 ± 58	4.24	
11c		1930 ± 90	>200 ± 0	4.24	
12a		3220 ± 550	>200 ± 0	5.76	5.60
12b		1220 ± 60	>200 ± 0	5.76	5.22
12c		130 ± 34	>200 ± 0	5.76	5.15
18a		1315 ± 256	>100	6.66	
18b		306 ± 46		6.66	

^aEnzyme concentration is 100 nM.

^b ClogP values determined using ChemDraw 8.0.